CIRIUM
16.1.2024 10:01:26 CET | Business Wire | Press release
Two of the top five global airports for on-time performance hailed from India this year, in Cirium’s annual On-Time Performance Review.
Rajiv Gandhi International Airport came second in the global rankings with 84.42% of flights on time, and Kempegowda International Airport hot on its heels with 84.08% of flights on time, in third place.
There was also a top place finish in the medium airports category for another APAC airport, with Osaka International Airport who managed an impressive 90.71% of flights on time. There was a second-place finish in the small airports category for Chubu Centrair International Airport (NGO) with 90.17% of flights on time, just 0.12% behind the top spot.
It should also be noted that Indigo Airlines was achieved an impressive fourth place in punctuality for the Asia Pacific Airline category with 82.12% of its flights arriving on-time. While operating nearly 680,000 flights in 2023.
An on-time flight is defined as a flight that arrives within 15 minutes of the scheduled gate arrival. For an airport, it is defined as departing within 15 minutes of its scheduled departure.
Jeremy Bowen, CEO of Cirium, said: "Cirium’s annual On-Time Performance Review is a global assessment of the punctuality of all types of carriers and airports, as evidenced by the widespread representation of operations from each corner of the globe, in this year’s review. Indian airports performed particularly well, with podium finishes in the global and large airport categories, and there was further representation for the APAC region in the other two airport categories as well. I’d like to extend my congratulations to all the featured airlines and airports in this year’s review.”
Now in its 15th year, the Cirium On-Time Performance program continues to meticulously monitor global airline operational performance. Our extensive and unbiased data, derived from over 600 real-time information sources, is essential for industry stakeholders. Our data encompasses airlines, airports, global distribution systems, civil aviation authorities, and more, ensuring a comprehensive and neutral perspective.
Cirium is continuing to lead the way, worldwide, in monitoring aviation on-time performance in the New Year, as the industry adjusts to post-pandemic norms. The company’s data and analytics are designed to provide industry stakeholders with a neutral, third-party perspective, based on the widest and deepest pool of information collected and curated from more than 600 sources of real-time flight information.
These include the airlines themselves, airports, global distribution systems, positional data, civil aviation authorities, air navigation service providers, proprietary data partnerships and the internet. Cirium’s on-time performance data is backed by a completely independent board of advisors, comprised of industry experts with an unbiased view of the aviation sector. The board’s oversight ensures accuracy and proper representation of all the information the company presents.
The top performing global airports of 2023 were:
Airport |
On time ranking |
On time departure |
Total flights |
Minneapolis-St. Paul International Airport (MSP) |
1 |
84.44% |
289,817 |
Rajiv Gandhi International Airport (HYD) |
2 |
84.42% |
168,426 |
Kempegowda International Airport (BLR) |
3 |
84.08% |
237,461 |
El Dorado International Airport (BOG) |
4 |
84.01% |
292,486 |
Salt Lake City International Airport (SLC) |
5 |
83.99% |
226,705 |
The top Asia Pacific Airlines of 2023 were:
Airline |
On time ranking |
On time arrival |
Total flights |
All Nippon Airways (NH) |
1 |
82.75% |
302,279 |
Japan Airlines (JL) |
2 |
82.58% |
308,302 |
Thai AirAsia (FD) |
3 |
82.52% |
113,871 |
IndiGo (6E) |
4 |
82.12% |
678,446 |
Air New Zealand (NZ) |
5 |
79.68% |
175,876 |
The full 2023 On-Time Performance Review is available for download at Cirium.com/on-time-performance
About Cirium
Cirium is the world’s most trusted source of aviation analytics. Through powerful data and analytics, coupled with decades of industry experience, Cirium is enabling airlines, airports, travel companies, aircraft manufacturers, and financial institutions, amongst others, to make intelligent and informed decisions that improve operations, grow revenues, and enhance customer experiences.
Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116289335/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom